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Abstract
We present a patient with chemotherapy-refractory Chronic Lymphocytic 
Leukemia (CLL) in whom postmortem examination showed hepatosplenomegaly, 
with both multiple small-cellular CLL lesions and large-cellular, monoclonal 
T-cell infiltrates. Following this case, the co-incidence of T-cell malignancies and 
CLL was studied using Dutch and American cancer registry databases. Analysis 
showed an excess risk for T-cell malignancies in CLL patients, with increased 
standardized incidence ratios compared with the general population and all 
cancer survivors in the databases. We hypothesize that CLL cells interact with 
T-cells in the microenvironment, facilitating malignant transformation.
Keywords: Chronic lymphocytic leukemia; T-cell lymphoma; Neoplastic cell 
transformation; Cohort studies
Introduction
Chronic Lymphocytic Leukemia (CLL) is a chronic 
lymphoproliferative disorder characterized by progressive 
accumulation of mature B-cells in peripheral blood and secondary 
lymphoid organs. Primary causes of death include infections and 
secondary malignancies [1], suggesting an immunodeficiency in 
CLL patients [2]. Recent epidemiological data demonstrated that 
the increased risk of other primary malignancies in CLL patients is 
independent of treatment or surveillance bias [3]. Most likely, CLL is 
not a disease limited to B-cells only, but also affects other components 
of the immune system due to extensive crosstalk between CLL cells 
and their microenvironment [4]. In this report, we present a patient 
with therapy-refractory CLL in whom post-mortem examination 
revealed the presence of a T-cell lymphoma. We further studied the 
coincidence of T-cell malignancies and CLL within two population-
based cancer registries, and found an excess risk of T-cell malignancies 
in patients with CLL. 
Case Presentation
A 75-year-old male patient with therapy-refractory CLL was 
referred to our hospital. CLL had been diagnosed 7 years earlier 
(initially Rai 0) and during the last 3 years, he was intermittently 
treated with Chlorambucil. One month before admission, he had a 
painful cervical node, from which a biopsy revealed CD5 positive, 
cycline-D1 negative B-cells, compatible with CLL and without 
signs of transformation. Upon admission, patient presented with 
fever, dysphagia, and general malaise. His blood counts showed 
a pancytopenia with hemoglobin 7.9 g/dL (12.1 a month before), 
leukocytes 2,300/μl (50% lymphocytes), and platelets 10,000/μl 
(80,000 before). Without clinical signs of a specific infection, he was 
treated with broad-spectrum antibiotics. A bone marrow biopsy was 
performed, showing80% CLL cells (positive for CD5/CD19/CD23/
CD20dim) and dysplasia in the myeloid and erythroid lineages. 
Within hours, he had progressive respiratory failure due to either 
sepsis or transfusion-related lung injury. Despite ventilatory support, 
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patient’s condition rapidly deteriorated and he died within a few 
hours.
Post-mortem examination showed signs of multi-organ failure, 
including congested lungs without microbial infiltrates. There was 
hepatosplenomegaly and lymphadenopathy. Immunohistochemistry 
studies showed diffuse infiltrates of small, basophilic cells, positive 
for CD5, CD20 and CD23 (in liver, spleen, and bone marrow). 
Remarkably, the spleen contained, apart from CLL, areas with large 
cells with atypical nuclei positive for CD3, CD8, and Granzyme B, 
and negative for CD4, CD5, CD20, CD23, CD30, ALK1, CD79a, 
PAX-5, EBV, and keratin.Ki67 showed a high proliferation index 
in these areas. Altogether, this patient was found to have CLL and a 
high-grade peripheral T-cell lymphoma NOS (Figure 1). Molecular 
analyses of both spleen and liver lesions demonstrated clonal B-cell 
receptor and clonal T-cell receptor rearrangements, confirming both 
malignancies. Analysis was also performed on banked peripheral 
Figure 1: Spleen section with T-cell lymphoma (*) and CLL, stained 
with (A) H&E, (B) CD79a, (C) CD3, (D) CD5 monoclonal antibodies (50x 
magnification). 
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blood from 3 years earlier, excluding the presence of the malignant 
T-cell clone at an earlier stage of disease.
This case demonstrated that a large-cell T-cell lymphoma had 
developed in a patient with a chronic B-cell leukemia. In the classical 
Richter’s syndrome, CLL cells are believed to transform into a large 
cell B-cell lymphoma, after acquisition of additional molecular lesions 
[5]. Rarely, in large cellular lymphomas complicating CLL, there is 
any clonal relationship with CLL. There have been case reports of 
Hodgkin’s disease [6-8] and T-cell lymphoma [9-11] found in CLL 
patients.
Cohort study
To estimate the incidence of T-cell lymphomas among CLL 
patients, we performed a retrospective study within the Netherlands 
Cancer Registry (NCR) database. We retrieved all cancer cases 
diagnosed in the Netherlands between 1989 and 2008 and included 
patients diagnosed with a first primary invasive cancer (n =1,270,595). 
Patients were followed until the occurrence of T-cell lymphoma, 
death, or end of follow-up (December 31, 2008). The order of the 
cancer diagnosis was determined according to the International Rules 
for Multiple Primary Cancers (ICD-O, [12]). All T-cell malignancies 
diagnosed after CLL diagnosis were included, using ICD-O-2 codes 
9700-9702, 9705, 9708, 9714, 9716-9719, 9827, 9831, 9834, 9948 
and ICD-O-3 codes 9591, 9593, 9675, 9680, 9684, 9702-9704, 9713, 
9823, 9825 combined with type=T-cell. As a measure of excess risk, 
Standardized Incidence Ratio (SIR) was calculated as the ratio of the 
observed number of cases in the cohort to the expected number of 
cases. The number of expected cases was calculated by multiplying the 
person-years at risk by the age-, gender-, and calendar year-specific 
incidence rates in the background population. 95% Confidence 
Intervals (95% CI) for SIRs were calculated based on a Poisson 
distribution. SAS software (SAS system 9.3, SAS Institute, Cary, NC) 
was used to perform the statistical analyses.
As shown in Table 1, Dutch CLL patients exhibited a threefold 
excess risk of developing a T-cell malignancy when compared with 
the entire Dutch population (SIR 3.0; 95% CI, 1.3-5.8). To correct 
for possible increased detection among cancer survivors, we also 
compared CLL patients with all Dutch cancer survivors. This yielded 
a SIR of 1.7, however statistically non-significant (95% CI, 0.71-3.3). 
As this might be due to the small size of the cohort, we performed 
the same analysis on the Surveillance, Epidemiology and End Results 
(SEER) database. We retrieved all registered cancer cases diagnosed 
in the United States (US) of America between 1973 and 2010 and 
included patients diagnosed with a first primary invasive cancer 
(n =6,316,679). End of follow-up date was December 31, 2010. We 
found that US CLL patients exhibited a more than two-fold risk for 
T-cell malignancies compared with all US cancer survivors (SIR 2.1; 
95% CI, 1.7-2.7).
Discussion
We here presented a patient with therapy-refractory CLL who 
died from multi-organ failure, in whom a T-cell lymphoma was 
detected at post-mortem examination. Within the Dutch NCR and 
larger US SEER databases, the epidemiological data corroborate the 
hypothesis that CLL predisposes patients for the development of 
T-cell malignancies. Indeed, there is a biologic rationale for increased 
incidence of clonal T-cell disorders in CLL. In CLL, there is an 
expansion of T-cells with a globally impaired function characterized 
by a pseudo-exhausted phenotype [13]. Also, microarray and 
functional studies showed that T-cells from CLL patients undergo 
significant changes on a molecular and structural level [14]. Clearly, 
CLL cells and T-cells have reciprocal interactions, inducing both 
expansion and intrinsic changes, and possibly facilitating malignant 
transformation. Of note, other factors may play a role in the 
pathogenesis of T-cell malignancies in CLL patients. We cannot 
exclude that previous treatment and/or immunosuppression would 
contribute to the pathogenesis of T-cell malignancies. In previous 
case reports, treatment with Chlorambucil, Fludarabine, and various 
immunosuppressive agents were described [10,11]. Compared with 
untreated follicular lymphoma patients, untreated CLL patients have 
a two-fold increased risk of second malignancies, as shown in a large 
Canadian cohort study [3]. Prolonged Chlorambucil treatment was not 
associated with an increase in second malignancies in a cohort of CLL 
patients [15], whereas most recently Benjamini et al. demonstrated 
that frontline treatment with Fludarabine, Cyclophosphamide, and 
Rituximab was associated with an increased risk of therapy related 
acute myeloid leukemia and Richter’s syndrome [16]. In these cohort 
studies, no cases of T-cell malignancy were described.
In conclusion, albeit the low incidence, CLL patients have 
an increased risk of developing T-cell malignancies. It remains 
to be established whether malignant transformation of T-cells is 
facilitated by interactions with CLL cells, direct mutations induced by 
chemotherapy, or deficiency in adequate immunosurveillance related 
to CLL and/or use of immunomodulating agents.
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